Podcasts about mutated

This week on Exploit It, we're diving into the chaotic waters of Cocaine Shark! Mutated predators, over-the-top action, and pure exploitation madness—sink or swim? Tune in to hear our take!

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/GZE865. CME/MOC credit will be available until December 21, 2025.Refining the First Strike Against EGFR-Mutated Advanced NSCLC: Personalizing Frontline Treatment Decisions Amid Increasing Complexity In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

AP correspondent Jackie Quinn reports on apparent mutations found with the bird flu virus detected in a person earlier this month.

The incidence of brain metastases is higher in patients with non-small cell lung cancer (NSCLC) than in patients with most other cancers, and the development of brain metastases is associated with poor prognosis. The objective of the podcast is to provide information about current and future treatments for brain metastases that develop in patients with EGFR-mutated NSCLC. The panel discusses surveillance and management of patients with brain metastases, different types of currently used treatments, and recent data on the intracranial efficacy of antibody–drug conjugates (ADCs). The panel also discusses current and future studies of ADCs in patients with EGFR-mutated NSCLC with brain metastases. This podcast discussion, among four oncologists (two thoracic oncologists, one radiation oncologist, and one neurologist/neuro-oncologist), is for healthcare professionals (HCPs) at community practices and research institutions.   This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00315-1. All conflicts of interest can be found online.    Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.   This podcast is intended for medical professionals.

In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was rejoined by Stephen Liu, MD, a thoracic oncologist and the Head of Developmental Therapeutics at Georgetown University's Lombardi Comprehensive Cancer Center in Washington, DC.  Their conversation encompassed findings from the phase 3 MARIPOSA trial (NCT04487080) investigating amivantamab-vmjw (Rybrevant) plus lazertinib (lacluze) in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC); toxicities associated with amivantamab and lazertinib to be aware of; the potential future implications of findings from the phase 3 PALOMA-3 trial (NCT05388669) of lazertinib plus subcutaneous amivantamab in patients with EGFR-mutated advanced or metastatic NSCLC; and how all these agents may fit into the NSCLC treatment armamentarium going forward.

Join us for another riveting Coffee Time Wednesday! And don't forget your Wild Rivers Coffee while you are at it, the best coffee that fights for conservation!   hokseynativeseeds.com (for CRP and Wildlife Habitat Mixes) theprairiefarm.com (for backyard prairie and wildflowers)

Please visit answersincme.com/860/93496951-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

This week on Game Crunch: S.T.A.L.K.E.R. 2: Heart of Chornobyl, Dungeon Clawler, Mario & Luigi: Brothership and rumors of a new PlayStation portable system. All this and more on the latest Game Crunch! Until next week - Game On!

New Orleans style brass meets DnB. Teamed up with AJ from Mutated forms on this one. Loved working on these horns! Streaming links: https://cygnusmusic.link/qeo7pjm Bag a copy here: https://www.junodownload.com/products/heavy-beat-brass-beer-pong-aj-mutated-c/6839443-02/ AJ Mutated @ajmutated www.instagram.com/ajmutated C@ In The H@ @c-in-the-h www.instagram.com/dj.cat.in.the.hat/ Heavy Beat Brass Band www.heavybeatbrass.com/ www.facebook.com/HBbrass

Drs Park and Liu explore advancements in the management of EGFR-mutated NSCLC, highlighting clinical trial updates shaping current treatment strategies.

I don't know if you can ever really prepare for a significant perspective shift in a way that self-indulgent self development  makes it feel. The whole time you're working towards being better, remembering what it's like to be in a body you've never left.  I love when an online scroll bears fruit. I saw a video from a TikTok creator called Beyond Codependant who shares their matrix of people pleasing. WHICH INVOLVES MORE ARCHETYPES OF PEOPLE PLEASERS. SO COOL.  There's the people manager, the caretaker, the matcher, and of course, the classic people pleaser. In exploring how these roles show up in relationships, it's reminding me why it's important to get to know your faves deeply. Not scripting through the relationship. And because you know I love it, I also tie it all into astrology — especially the 11th house — to explain how your sign and modality can influence your social dynamics.  In the spirit of sharing, I'll also open up about my own experiences with setting boundaries, managing relationships, and the power of being self-aware. It's like a cosmic roadmap to healthier connections, with a little DIY fashion inspiration thrown in. ✨

When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya Sankar, MD, assistant professor and co–medical director of the Thoracic Disease Research Group at Cedars-Sinai Cancer Center in Los Angeles. Recent approvals by the U.S. Food and Drug Administration have introduced several “new friends,” in the form of amivantamab (Rybrevant) and lazertinib (Lazcluze). Dr. Sankar talks with Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology also at Cedars-Sinai Cancer Center, about how to choose among osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab plus lazertinib. Without overall survival data available for all choices, Dr. Sankar explains how she and her patients decide which treatment is best, as well as how to consider sequential therapy after disease progression. Dr. Sankar reported no relevant financial relationships. Dr. Figlin reported various financial relationships.

I Spent The Night In A Forest In Chernobyl With Mutated Animals. I Found A List Of Rules! Creepypasta

Therapeutic options for frontline management of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) are rapidly evolving. Are you up to date on the evidence?    Credit available for this activity expires: 09/27/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001657?ecd=bdc_podcast_libsyn_mscpedu

BUFFALO, NY- October 11, 2024 – A new #editorial was #published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.” As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG). TP53-mut AML is inherently resistant to conventional chemotherapies and continues to show a poor prognosis, even with venetoclax-based therapies. Allogeneic hematopoietic stem cell transplant (allo-HCT) remains a potential curative option, though only 10–15% of patients receive it. In a recent study, allo-HCT was the only variable significantly improving survival, despite only 16% of patients successfully bridging to it. In their editorial, researchers Talha Badar, Moazzam Shahzad, Ehab Atallah, Mark R. Litzow, and Mohamed A. Kharfan-Dabaja from the Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic (Jacksonville, Florida) evaluated the outcomes of TP53-mutated AML patients based on data from the Consortium of Myeloid Malignancies and Neoplastic Diseases (COMMAND). The study found a “dismal” survival rate of 8.5 months, with no significant difference among treatment types, and allo-HCT was the only variable associated with improved survival. The authors also report on the “better long-term outcomes” when allo-HCT was performed during Complete Remission 1 (CR1) in previous observations. They acknowledge the limitations of their retrospective analysis, including selection bias, data heterogeneity from participating institutions, and the lack of complete molecular data prior to allo-HCT that might have influenced the results. Nevertheless, the findings are encouraging and suggest that allo-HCT improves long-term outcomes in this poor prognostic disease, where effective therapies remain limited. “In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.” DOI - https://doi.org/10.18632/oncotarget.28652 Correspondence to - Talha Badar - badar.talha@mayo.edu Video short - https://www.youtube.com/watch?v=OQue9gbqsxE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28652 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, AML, TP53 mutation, allogeneic stem cell transplant About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME information, and to apply for credit, please visit us at PeerView.com/EQU865. EBAC/CME credit will be available until October 6, 2025.Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC: A Practical Framework for Optimal Biomarker Testing, Treatment Selection and Sequencing, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

Send us a textOn this episode I talk all things creature features with my friend Anastasia Elfman. This is part 1 of a 2 part series. We talk everything from cats to Mutated monsters.ANASTASIA ELFMAN: TIK TOKYOUTUBEINSTAGRAM FACEBOOKRICHARD ELFMAN:INSTAGRAM FACEBOOK YOUTUBEBLOODY BRIDGET INSTAGRAMBLOODY BRIDGET FACEBOOKALIENS, CLOWNS & GEEKS FACEBOOKFORBIDDEN ZONE FACEBOOKFORBIDDEN ZONE INSTAGRAM Synth Outro by Abraxas HornMy email and social links:Brandonlegion666@yahoo.comTwitter: Horrorwolf666Instagram: Brandonlegion666 Facebook: Horrorwolf666Website: www.horrorwolf666.com(Merchandise)https://www.teepublic.com/user/the-horrorwolf666-podcasthttps://the-horrorwolf666-podcast.creator-spring.com/

In today's show, our hosts Tracey and Scott discuss a new series on Disney Plus: LEGO Star Wars: Rebuild the Galaxy - touching on its production as well as  their thoughts.  They'll also explore the history between Lego and Star Wars.  Additionally, per their request on the last episode, they received some recordings of Storytime with Deadpool at Avenger's Campus at the Disneyland Resort that they'll share. A very special thank you to Brian Babcock for his invaluable assistance in this episode. Welcome to Disney, Indiana

Subscribe: iTUNES, RSSSupport Us On PatreonDiscuss This EpisodeEmail UsLINKS:DiscordRedditEmailWorldbuilding NotesWorldbuilding Notes (Book Notes playlist)Always Coming Home (Ursula K. Le Guin)PotiononomicsAnathem (Neil Stephenson)Erusk JournalMusic:"SCP-x2x (Unseen Presence)" Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 Licensehttp://creativecommons.org/licenses/by/4.0/Thanks for listening, everyone. ❤️

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Genentech decide to remove Fuzeon from US market; Rybrevant and Lazcluze approved as first-line treatment for certain patients with EGFR-mutated advanced NSCLC; FDA warning regarding unapproved potassium phosphates; Otezla approval expanded to include treatment of pediatric patients; Results from tirzepatide diabetes risk reduction study.

Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer.

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individualsMolecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLCD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

BUFFALO, NY- August 14, 2024 – A new #casereport was #published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.” As noted in the introduction of the Abstract, the BRAF V600E substitution predicts a cancer's sensitivity to BRAF inhibitor therapy, though the mutation is rarely found in soft-tissue sarcomas. Researchers Kseniya Sinichenkova, Iliya Sidorov, Nataliya Kriventsova, Dmitriy Konovalov, Ruslan Abasov, Nataliya Usman, Alexander Karachunskiy, Galina Novichkova, Dmitriy Litvinov, and Alexander Druy from the Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology (Ministry of Healthcare of Russian Federation) and the Research Institute of Medical Cell Technologies in Yekaterinburg, Russia, describe a case of undifferentiated spindle cell sarcoma that exhibited primary insensitivity to standard chemotherapy and a pronounced but non-sustained response to BRAF/MEK inhibitors at recurrence. The case presentation involved a 13-year-old girl that was diagnosed with low-grade spindle cell sarcoma of pelvic localization, BRAF exon 15 double-mutated: c.1799T>A p.V600E and c.1819T>A p.S607T in cis-position. “This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.” DOI - https://doi.org/10.18632/oncotarget.28606 Correspondence to - Kseniya Sinichenkova - ksinichenkova@gmail.com Video short - https://www.youtube.com/watch?v=QWEAaaixPxE Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28606 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, undifferentiated sarcoma, BRAF V600E mutation, low grade spindle cell sarcoma, abdominal cocoon About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of the "Giant Mess" podcast, movie lover Neal Lynch recaps and reviews Deadpool and Wolverine, the most Deadpool movie in the history of Deadpool, a meta buddy comedy that ushers in the Mutant Era of the Marvel Cinematic Universe. Deadpool and Wolverine is the first R-rated movie in the MCU, the first R-rated movie directly distributed under Walt Disney Studios Motion Pictures, and the first R-rated movie to cross $200 million domestically in its opening weekend. Cast Ryan Reynolds as Wade Wilson / Deadpool: A wisecracking mercenary from Earth-10005 with accelerated healing but severe scarring over his body after undergoing an experimental regenerative mutation to treat terminal cancer Writer Rhett Reese described Deadpool as a fish-out-of water in the film, a lunatic dropped into the "sane world" of the Marvel Cinematic Universe (MCU). Hugh Jackman as James "Logan" Howlett / Wolverine: A former member of the X-Men and a mutant with healing abilities, retractable claws, and an adamantium-infused skeleton. Matthew Macfadyen as Mr. Paradox: A Time Variance Authority (TVA) agent who oversees an unsanctioned project to speed up the death of Earth-10005 by using the "Time Ripper", a machine which can mercy kill timelines. Paradox hopes to prove himself with this to become the leader of the TVA.Synopsis: Deadpool is offered a place in the Marvel Cinematic Universe by the Time Variance Authority, but instead recruits a variant of Wolverine to save his universe from extinction. Deadpool's peaceful existence comes crashing down when the Time Variance Authority recruits him to help safeguard the multiverse. He soon unites with his would-be pal, Wolverine, to complete the mission and save his world from an existential threat. Movie Reviews from Giant Mess Podcast - https://bit.ly/GiantMessMovieReviews TV Show Reactions from Giant Mess Podcast - https://bit.ly/GiantMessTV Funny Stories from Giant Mess Podcast -  https://bit.ly/GiantMessFunnyStories  ABOUT NEAL LYNCH: I'm an Irish-Italian-American who graduated from 1) a Catholic high school (even though I'm not Catholic), and 2) a college known for producing doctors and lacrosse players, then became neither. I was a former 4th string college quarterback and middle relief pitcher who thought an overpriced film and media studies degree was a smart choice. Now, I'm a single dad who likes to blog, vlog, podcast, write, edit, optimize, strategize, and over-analyze.   ABOUT "GIANT MESS": "Giant Mess" is a sloppy sports and entertainment talk show hosted by a giant mess, the Real Cinch Neal Lynch. Neal's a single dad who loves to talk New York Giants football, Mets baseball, movies, TV shows, and comedy. The podcast has movie reviews, tv show recaps and reactions, post-game analysis, predictions, and funny stories about life. I've written three feature length screenplays, plus thousands of articles including posts for COED, GuySpeed, TheFW, TV Fanatic, G-MEN HQ, BroBible, and NFL Spin Zone.  I've also authored scripts for Woven Digital's short-form videos published by UPROXX and BroBible.  Here are links to my writing samples: NFL Spin Zone http://nflspinzone.com/author/neallynch/   BroBible http://brobible.com/author/neallynch/   GmenHQ http://gmenhq.com/author/neallynch/   TV Fanatic - https://www.tvfanatic.com/authors/neal-lynch/   Subscribe to Giant Mess on YouTube: https://bit.ly/GiantMessYT    Follow me on: Link Tree - https://linktr.ee/neallynch  My Official Blog - http://bit.ly/neallynchBLOG   Giant Mess Facebook Page - http://bit.ly/GiantMessFB    Twitter - http://bit.ly/NealLynchTW      Personal Instagram - http://bit.ly/NealLynchIG    Giant Mess Instagram - https://bit.ly/GiantMessInstagram  Subscribe to Giant Mess on Apple Podcasts - http://bit.ly/GiantMessApple    Subscribe to Giant Mess on Spotify - http://bit.ly/GiantMessSpotify 

This week Casey and Brent chat about Brent's time at Too Many Games, painting live in front of an audience, hobby projects we have been working on and much more! Once again, it's ridiculous, but we hope you got some hobby done while listening, and we want you to know that we very much appreciate you :) ___________________________________________________________________________________ MERCH: Would you believe it we actually have merch for sale? If you would like to support this podcast and help keep it going, this is a tremendous (and currently only) way to do so, otherwise, we absolutely appreciate your support through subscribing and commenting, thank you! General Store: https://teespring.com/paint-bravely?pid=1027&cid=104079 ___________________________________________________________________________________ YOUTUBE CHANNEL LINKS: eBay Miniature Rescues http://www.youtube.com/ebayminiaturerescues Goobertown Hobbies http://www.youtube.com/goobertownhobbies ___________________________________________________________________________________ EQUIPMENT: We use Skype to monitor video record independently on Panasonic GX85 cameras. This all gets edited down into a visual and audio podcast by our editor Matt! Music: EpidemicSound

The disciples had just returned from a week of powerful ministry. Jesus, however, seemed to pour cold water on their rejoicing—and for a very, very good reason… (Luke 10:17-24)

In hour two, Mike & Jason talk the latest baseball news with MLB Network's Adnan Virk (3:00), the boys argue about which Canucks jersey is best (20:00), they chat the Canadian Open with Sportsnet golf analyst Adam Stanley (27:00), plus Halford defends his "no jersey" rule (47:00). This podcast is produced by Andy Cole and Greg Balloch. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Media Inc. or any affiliate.

Nick Cage and his "sons" live a peaceful rustic lifestyle in a dystopian monster filled hellscape. Whats not to love? --- Send in a voice message: https://podcasters.spotify.com/pod/show/cinekuest-video/message Support this podcast: https://podcasters.spotify.com/pod/show/cinekuest-video/support

Today I play mutated Duels

Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.

Special Guest E. Reyes of "E Reyes Horror" and Author of Evening of the Mutated Undead is on to talk about his book. We dissect his love and passion for zombie fiction. We dive into his inspiration for the book and the creative process behind his work. Top 3 zombie film break down and dream director for the film adaptation are all discussed! When there is no more room on Spotify, ROR will walk the Earth.https://www.teepublic.com/user/ruminationsradionetworkwww.RuminationsRadioNetwork.comwww.instagram.com/ruminationsofredrumhttps://twitter.com/OfRedrumwww.instagram.com/RuminationsRadioNetworkTwitter: RuminationsRadioNetwork@RuminationsNhttps://www.patreon.com/RuminationsRadioMusic and Production by Mitch Proctor for Area 42 Studios and SoundEpisode Artwork Charles Langley and Mitch Proctor for Area 42 Studios and Soundhttps://www.patreon.com/RuminationsRadio ★ Support this podcast on Patreon ★

Bonus episode about impact of the atomic age on food Hosted on Acast. See acast.com/privacy for more information.

On this week's episode, was Darin reading an adult novel in the airport? Plus, Mike goes deep in conversation about why bananas don't taste like they're actually supposed to.And Darin finally saw John Wick 4. You don't want to miss his reviewDon't forget to tune in next week for our 200th episode and go to our website to buy a shirt!#THECANADIANMOUNTED#PLANESTRAINSANDAUTOMOBILES#BANANAS#CHICAGO#BOBNEWHART#UNITEDAIRLINES#BISCOFFCOOKIES#RAMBO#JOHNWICK4Support the show

It's time for the Comic Talk Headlines with Generally Nerdy! Mr Beast is possibly about to legitimize the Creator Sphere for all of us!Eternals 2 has evolved... or MUTATED if you will.And so much more...Plus, don't forget to subscribe for more fresh content.   MusicFollow-ups/CorrectionsShadows Fall - Sounds like we will be getting that new album SOON-ish. Brian told WSOU 89.5 FM that there might be a different release strategy this time around since there is no label pressure. So far the band claims to have around 6 or 7 new tunes recorded so far, with a vinyl planned in the end.https://blabbermouth.net/news/shadows-fall-has-six-or-seven-new-songs-recorded-so-far-we-wanna-get-it-as-perfect-as-we-can New Music/VideoSebastian Bach - “Everybody Bleeds” https://youtu.be/_wx4PQRx2hA Really cool bass tone. Kinda what you would expect from an 80s icon. “Child Within the Man” record to release May 10.Vended - The Far Side https://youtu.be/AhglyV90Cbg Griffin Taylor and Simon Crahan's father's influence is showing a bit here. But less so than in previous outings. These kids just keep getting better.Dead Icarus - Ad Infernum https://youtu.be/RF-rJ2Fy-Gc Newest single from the EP with the same title.Burton C Bell - Anti-Droid https://youtu.be/ejssq84_4TA Slow burn compared to his previous work.Eminem - Doomsday 2 https://youtu.be/Evut8BfrZ2U SO SHORT?!!Immortal Disfigurement - Showcase OV Phlegm https://youtu.be/TWYThpTgw-g CJ does what he does VERY DAMN WELL! Glad to see that the drama has been sorted for this release at leat. Exercising their melodic sideZao - Croatoan https://youtu.be/VbhPp1NhW3I New live album “Live From the Church.” Definitely a different ZAO than I remember. A little more POST-metal influence it seems. Lots of layers and atmosphere.Avenged Sevenfold - Cosmic https://youtu.be/NxFE5YOErcg This is more what I would expect from the guys at this point in their career.Tours/FestivalsHe Is Legend - May 3 in Philadelphia, PA through June 8th in Columbia South Carolina. Support from Codeseven, The Seafloor Cinema, and Johnny Booth on the last few.https://www.stubhub.com/he-is-legend-tickets/performer/1495250 Hatebreed - 30th anniversary tour featuring  Carcass, Harms Way, and Crypta. Sept 26 in Portland Maine through Oct 27 in Norfolk Virginia.https://www.stubhub.com/hatebreed-tickets/performer/404873 Reg ‘ol NewsJourney - “Don't Stop Believin” recognized by Forbes as the biggest song of all time. The RIAA has certified the song 18x PLATINUM!https://blabbermouth.net/news/journeys-dont-stop-believin-recognized-as-biggest-song-of-all-time Pantera - Live album? Charlie Benante says there have been conversations.https://blabbermouth.net/news/charlie-benante-says-there-has-been-talk-of-current-pantera-lineup-releasing-a-live-album Slipknot - Anders Colsefni has re-recorded the original release from the band with a new line-up, as a tribute to the memories of Paul and Joey. https://blabbermouth.net/news/original-slipknot-vocalist-anders-colsefni-releases-new-version-of-mate-feed-kill-repeat SuggestsHe Is Legend - White Bat - He is Legend is an American hard rock/heavy metal band from Wilmington, North Carolina, formed in the late 1990s but settled on the name "He Is Legend" in 2003. The band's lineup is front man Schuylar Croom, guitarist Adam Tanbouz, bassist Matty Williams, and drummer Jesse ShelleyGaming/TechFollow-ups/CorrectionsMetal Gear Solid Master Collection Vol 1 - Konami is going to be patching the games in order to update the visuals. https://comicbook.com/gaming/news/metal-gear-solid-mgs-collection-updates-4k/ Overwatch 2 - All heroes will be available for free starting in season 10. No release date yet. https://comicbook.com/gaming/news/overwatch-2-season-10-free-heroes/ TrailersAnimal Well - https://youtu.be/qhB6dLh9nn4 Metroidvania style game from Videogamedunkey's production studio Big Mode. Releasing on May 9th.Reg ‘ol NewsTikTok - The US Bill to divest the company from ByteDance has passed. https://wegotthiscovered.com/pop-culture/tiktok-ban-passed-the-protecting-americans-from-foreign-adversary-controlled-applications-act-explained/ Mr Beast - Getting a new game show on Amazon Prime. 1000 contestants competing for $5M. Taking his time so as to NOT embarrass the creator space. SUPER AWESOME!https://variety.com/2024/tv/news/mrbeast-prime-video-reality-show-beast-games-1235944550/ https://youtu.be/4FRYox-sPP8 Apex Legends - The North American finals of the Apex official Esports tournament had to be post-poned due to hacks. But not just any hacks, but Kernel level Easy Anti-Cheat hacks, the very same that LTT have been warning us about for some time at this point. https://www.engadget.com/hackers-gave-pro-players-cheats-during-eas-north-american-finals-of-apex-legends-122102739 Nvidia - In their press event on Monday CEO Jensen Huang revealed the next step in AI focused GPUs. The GH200 chip is four times more powerful than Nvidia's previous H100. When incorporated into Nvidia's new DGX GV100 system, the GH200 can achieve 30 times better inference performance at 25 times lower energy consumption compared to previous systems.It enables running large language models (LLMs) with up to 27 trillion parameters, surpassing the cutting-edge GPT-4 model's 1.7 trillion parameters.https://www.engadget.com/nvidias-gpus-powered-the-ai-revolution-its-new-blackwell-chips-are-up-to-30-times-faster-001059577.html Apple VS Google - Apple wants to use Google's AI technology, called Gemini, to power upcoming generative AI features in iOS 18, which is expected to release this year. The official announcement of just what exactly the deal is going to be is said to be happening at WWDC in June.https://www.engadget.com/of-course-apple-wants-to-bring-googles-gemini-ai-to-iphones-144604811.html Snapdragon - Qualcomm announced the Snapdragon 8s Gen 3 as a more affordable alternative to its flagship 8 Gen 3 chip. While less powerful, the 8s Gen 3 retains most key features and introduces an updated CPU and on-device generative AI support. Positioned between the budget and premium tiers, it succeeds last year's 7 Plus Gen 2 chip. However, Qualcomm's confusing naming conventions for its processors continue to lack clarity.https://www.engadget.com/qualcomms-snapdragon-8s-gen-3-chip-is-a-notch-below-its-flagship-processor-075258397.html SuggestsMK1Comic Books/BooksTrailersX-Men - https://youtu.be/QuyyM-Jlkas Marvel Comics announces three new titles with new creative teams which includes Jed MacKay and Ryan Stegman on X-Men, Gail Simone and David Marquez on Uncanny X-Men, and Eve L. Ewing and Carmen Carnero on Exceptional X-Men. Announced at SXSW X-Men: Krakoa is no more… but the X-Men fight on! From their new base in Alaska, the X-Men raise a flag of defiance! Join Cyclops, Beast, Magneto, Psylocke, Kid Omega, Temper (formerly Oya), Magik and Juggernaut as they assemble against new forces, battling for the destiny and philosophy of the mutant species. Mutant business is their business. Uncanny X-Men: Outlaw heroes once again, the X-Men embark on a new mission! Making themselves at home in the Big Easy, the X-Men protect a world that hates and fears them! Join Rogue, Gambit, Nightcrawler, Jubilee, and Wolverine on explosive super hero adventures. Uncanny as ever, the X-Men are back to saving the day mutant-style! Exceptional X-Men: Mutantkind's two greatest teachers mold the next generation of X-Men! Kate Pryde has returned home to Chicago following the war with Orchis. Having stepped away from the world of mutantdom, she is nevertheless called back into action as she crosses paths with a trio of new young mutants, Bronze, Axo, and Melee, who clearly need training and guidance. Unfortunately for Kate, Emma Frost thinks so as well!The art looks like the powers that be at Marvel are trying to shrug off some of the socio-political agenda from the recent past.Reg ‘ol NewsSpace Ghost - Dynamite Comics has secured the rights for the good old talk-show host. But the serious version. From the team of David Prepose (Punisher) and Jonathan Lau (Vampirella Strikes), Dynamite's new series looks like it's taking an edgier turn than the Hanna-Barbera cartoon that befits its period, and the studio's tongue-in-cheek style. https://www.dynamite.com/htmlfiles/viewProduct.html?PRO=C72513034479301011 https://youtu.be/4QnxJVUuSCs SuggestsJoker Year One - a four-part written by Chip Zdarsky with art by Giuseppe Camuncoli, Andrea Sorrentino, and Stefano Nesi, chronicling the origin of the Joker.Episodic ShowsFollow-ups/CorrectionsMarvel on Disney+ - Wonder Man and Ironheart, both, are in active production. It seems that neither has been canceled like rumors have suggested previously. https://cosmicbook.news/wonder-man-ironheart-not-canceled AHS: Delicate - Part 2 returns April 3rd. The Bear - renewed for a 4th season before season 3 ever airs.TrailersSuicide Squad Isakai - https://youtu.be/GqwUijRuKzc still looks good! Still no specific release, just sometime this year.Black Mirror -https://twitter.com/netflix/status/1768337596822774081 Season 7 confirmed for 2025 on Netflix. This season will have a sequel to the USS Callister from season 4.X-Men 97 - https://youtu.be/Ir2n4pegD8I previously on… Fallout - https://youtu.be/V-mugKDQDlg April 11 the FULL season. https://youtu.be/Z_7jXPMu0Nk Acolyte - https://youtu.be/BtytYWhg2mc Interview with the Vampire - https://youtu.be/w1DNtxOO0DI season 2 May 12.SuggestsInvincible - adult animated superhero television series created by Robert Kirkman for Amazon Prime Video. Based on the Image Comics series of the same name by Kirkman, Cory Walker, and Ryan Ottley, the show follows 17-year-old Mark Grayson and his transformation into a superhero under the guidance of his father Omni-Man, also known as Nolan Grayson, the most powerful superhero on the planet.MoviesFollow-ups/CorrectionsScream - Neve Campbell to return to the franchise for the next installment. Said to have increased their offer to keep her involved. This comes after Melissa Barrera and Jenna Ortega have each left the project for different reasons. Star Wars: Rogue Squadron - Patty Jenkins says she is back on the project.The American Society of Magical Negroes - Opens to $1.3M.Venom 3 - Venom: The Last Dance subtitle announced.TrailersThe Crow - https://youtu.be/djSKp_pwmOA looks better than that initial image suggested… though by how much remains to be seen.Rebel Moon Part Two: The Scargiver - https://youtu.be/UEJuNHOd8Dw Lots more non-sabre action it would seem.Furiosa - https://youtu.be/FVswuip0-co in theaters May 24.Reg ‘ol NewsTeen Titans - New movie announced. Ana Nogueira will write the script who is also writing the screenplay for the Supergirl: Woman of Tomorrow movie starring Millie Alcock for Gunn's DCU.https://cosmicbook.news/dcu-teen-titans-movie Popeye - Live-action movie reboot happening. Chemin Entertainment and King Features are putting the budget together to get behind a screenplay written by Michael Caleo.https://variety.com/2024/film/news/popeye-live-action-movie-chernin-king-features-1235945446/ Poohniverse - Producer Scott Chambers is putting together a horror movie universe. Blood and Honey 2, Bambi: The Reckoning, Peter Pan: Neverland Nightmare, Pinocchio: Unstrung, Poohniverse: Monsters Assemble.https://comicbook.com/horror/news/poohniverse-monsters-assemble-to-unite-winnie-the-pooh-bambi-and-pinnochio/ SuggestsRicky Stanicky - a 2024 American comedy film directed by Peter Farrelly. The film stars Zac Efron, Jermaine Fowler, Andrew Santino, Lex Scott Davis, Anja Savcic, Jeff Ross, William H. Macy, and John Cena.Rumor MillConfirmations/RefutationsRyan Gosling MCU - Said to have signed on for Ghost Rider or Dr Doom.New RumorsMoon Knight - Oscar Isaac not returning to play Marc Spector. Not because of scheduling or anythings, but because the new Fist of Khonshu is said to be Blade.Eternals 2 - Canceled? Or possibly just morphed into X-Men movie?Henry Cavill - ANOTHER new rumor. Sounds familiar. This one has him as a VARIANT of Wolverine for the Deadpool movie. NOT as the MCU's new Wolverine.James Bond - Aaron Taylor-Johnson (Kick-Ass) is reportedly signing the deal to become 007.Meta Quest 3 - Alleged leaks about Meta's upcoming Quest 3 virtual reality headset surfaced last week, with conflicting details emerging. Initial leaks seemed to depict a budget-friendly "Quest 3 Lite" without augmented reality capabilities. However, more recent alleged screenshots from an internal Meta meeting showed a headset with a front-facing camera array and marketing focused on "mixed reality," suggesting augmented reality features. The authenticity of these leaks remains uncertain, as the level of detail in the latter leak has raised doubts about its legitimacy, given the potential legal risks of leaking internal documents.Foldable Phones - Leaks suggest Samsung will cater to different segments of the foldable phone market with its upcoming Galaxy Z Fold 6, offering both a budget version around $800 and a high-end model, with the former making compromises like no S Pen support and a smaller battery. Meanwhile, an unconfirmed roadmap points to Apple joining the foldable fray in 2026 with its own foldable iPhone, which is expected to carry a premium price tag higher than Samsung's budget offering.You can support this show by visiting our merch store, or by leaving us an Apple Podcasts review.

Happy Monday! Sam and Emma speak with David Bellos, professor of Comparative Literature at Princeton University, to discuss his recent book Who Owns This Sentence?: A History of Copyrights and Wrongs, co-authored with Alexandre Montagu. First, Sam and Emma run through updates on Israel's targeting of Al-Shifa hospital, the false UNRWA accusations, Russian elections, US realtors, SCOTUS, the sale of US Steel, the Federal Reserve, and Donald Trump's legal woes, before parsing through objections from US representatives to the continued commitment to Israel's obvious lies about UNRWA. Professor David Bellos then joins, diving right into the contemporary distinctions between patents, trademarks, and the monstrous world of copyright, with the former two requiring applications and reapplications, while copyright allows for extensive, long-term monopoly over intellectual property for both individuals and corporations. After briefly touching on the concept of intellectual property writ large, Professor Bellos steps back to look at the initially parallel histories of patents and copyright, both birthed alongside the creation and dissemination of the printing press in 15th Century Venice to provide a distinction between the limited ownership of newly-authored works and the public domain of older and classical art, also touching on the much longer (and more severe) history of trademarks stretching back through the medieval times. Moving forward, Bellos then walks Sam and Emma through how the evolution of the world of intellectual property over the 18th and 19th Centuries largely took place in Western Europe, with Paris and London leading the way to the 1886 Berne Convention while other Western states like the US seriously lagged, also touching on the lack of ideology or even rationality behind the slow but steady expansion of these rights, before parsing through the US' 180º turn on intellectual property over the 20th Century as they came into their hegemonic station, not only signing onto Berne but forcing anyone who wanted help from the Neoliberal order to do so as well. Following a conversation on the particularly astounding role of employer or corporate ownership over intellectual property, they wrap up the interview with an assessment of IP's role in stifling creativity, how major media companies would react to a complete overhaul of IP law, and what ideal reforms to IP would look like. Sam and Emma also update us on the Aldaghma family's escape from Gaza. And in the Fun Half: Sam and Emma watch Bibi Netanyahu's response to Senator Schumer's call for new Israeli elections, John from San Antonio previews some of the biggest primary races in tomorrow's elections and touches on progressives' failures in California, and the MR Crew parses through the highlights from Donald Trump's insane rally for Bernie Moreno in Ohio – including an appearance from the January 6th Choir, and the differing responses to Trump's “bloodbath” comments and his comments on migrants not being people. Fox works to normalize Trump's actively genocidal rhetoric, Jo Snuffy and Kathy from South Dakota dive into the Biden Administration plan for a temporary aid port in Gaza, and Boeing's controversies grow as a whistleblower is found dead, plus, your calls and IMs! Check out David's book here: https://fit.princeton.edu/publications/who-owns-sentence-history-copyrights-and-wrongs Become a member at JoinTheMajorityReport.com: https://fans.fm/majority/join Check out Seder's Seeds here!: https://www.sedersseeds.com/ ; use coupon code Majority and get 15% off; ALSO, if you have pictures of your Seder's Seeds, send them here!: hello@sedersseeds.com Check out, and share friend of the show Janek Ambros's new documentary for The Nation, "Ukrainians in Exile" here!: https://twitter.com/thenation/status/1760681194382119399?s=20 Check out this GoFundMe in support of Mohammad Aldaghma's niece in Gaza, who has Down Syndrome: http://tinyurl.com/7zb4hujt Check out the "Repair Gaza" campaign courtesy of the Glia Project here: https://www.launchgood.com/campaign/rebuild_gaza_help_repair_and_rebuild_the_lives_and_work_of_our_glia_team#!/ Get emails on the IRS pilot program for tax filing here!: https://service.govdelivery.com/accounts/USIRS/subscriber/new Check out StrikeAid here!; https://strikeaid.com/ Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the ESVN YouTube channel here: https://www.youtube.com/esvnshow Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! http://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: http://majority.fm/app Check out today's sponsors: Earthbreeze: Right now, my listeners can receive 40% off Earth Breeze just by going to https://earthbreeze.com/majority! That's https://earthbreeze.com/majority to cut out single-use plastic in your laundry room and claim 40% off your subscription. Aura Frames: Right now, you can save on the perfect gift that keeps on giving by visiting https://AuraFrames.com. For a limited time, listeners can get 20 dollars off their best-selling frame with code MAJORITY. That's https://AuraFrames.com promo code MAJORITY. Sunset Lake CBD: Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech @BradKAlsop Check out Matt's show, Left Reckoning, on Youtube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com/ The Majority Report with Sam Seder - https://majorityreportradio.com/

Capitalism has changed. A century ago, capitalists amassed untold wealth by building and manufacturing goods, but today, our economy appears to be dominated by massive tech corporations that don't actually produce anything at all. Instead, these tech giants offer platforms—such as search engines, AI, or marketplaces—through which they extract profits from users. Adam speaks with Yanis Varoufakis, former finance minister of Greece, about his book Technofeudalism: What Killed Capitalism, exploring how this new form of capitalism jeopardizes our livelihoods and what measures we can take to safeguard our future from big tech. Find Yanis's book at at factuallypod.com/booksSUPPORT THE SHOW ON PATREON: https://www.patreon.com/adamconoverSEE ADAM ON TOUR: https://www.adamconover.net/tourdates/SUBSCRIBE to and RATE Factually! on:» Apple Podcasts: https://podcasts.apple.com/us/podcast/factually-with-adam-conover/id1463460577» Spotify: https://open.spotify.com/show/0fK8WJw4ffMc2NWydBlDyJAbout Headgum: Headgum is an LA & NY-based podcast network creating premium podcasts with the funniest, most engaging voices in comedy to achieve one goal: Making our audience and ourselves laugh. Listen to our shows at https://www.headgum.com.» SUBSCRIBE to Headgum: https://www.youtube.com/c/HeadGum?sub_confirmation=1» FOLLOW us on Twitter: http://twitter.com/headgum» FOLLOW us on Instagram: https://instagram.com/headgum/» FOLLOW us on TikTok: https://www.tiktok.com/@headgum» Advertise on Factually! via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.